Advertisement

Topics

[News] Midostaurin in -mutated acute myeloid leukaemia

21:54 EDT 29 Jun 2017 | The Lancet

In patients with acute myeloid leukaemia (AML) with an FLT3 mutation, the addition of midostaurin to standard chemotherapy significantly improves overall and event-free survival, new research suggests.

Original Article: [News] Midostaurin in -mutated acute myeloid leukaemia

NEXT ARTICLE

More From BioPortfolio on "[News] Midostaurin in -mutated acute myeloid leukaemia"

Advertisement
Quick Search
Advertisement
Advertisement